Patents Assigned to Karus Therapeutics Limited
-
Patent number: 11291669Abstract: The invention relates to a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one second agent selected from the group consisting of signal transduction pathway inhibitors, tumour immunotherapeutics, agents inhibiting the BCL2 family of proteins, agents inhibiting Mcl-1, proteasome Inhibitors, poly (ADP-ribose) polymerase (PARP) Inhibitors, aromatase inhibitors, conventional cytotoxic agents or a miscellaneous agent selected from abiraterone, ARN-509 and MYC inhibitors.Type: GrantFiled: April 22, 2020Date of Patent: April 5, 2022Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Andrew David Whale
-
Patent number: 10870624Abstract: The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors.Type: GrantFiled: August 2, 2017Date of Patent: December 22, 2020Assignee: Karus Therapeutics LimitedInventors: Stephen J. Shuttleworth, Cyrille D. Tomassi, Alexander R. L. Cecil, Somhairle MacCormick, William J. Nodes, Franck A. Silva
-
Patent number: 10668077Abstract: The invention relates to a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one second agent selected from the group consisting of signal transduction pathway inhibitors, tumour immunotherapeutics, agents inhibiting the BCL2 family of proteins, agents inhibiting Mcl-1, proteasome Inhibitors, poly (ADP-ribose) polymerase (PARP) Inhibitors, aromatase inhibitors, conventional cytotoxic agents or a miscellaneous agent selected from abiraterone, ARN-509 and MYC inhibitors.Type: GrantFiled: August 19, 2016Date of Patent: June 2, 2020Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Andrew David Whale
-
Patent number: 10533003Abstract: The present invention is a compound having the following formula: or a pharmaceutically acceptable salt thereof, wherein e.g. L and Y are each independently an optionally substituted 6-membered nitrogen-containing heteroaryl; M is an optionally substituted 5- to 10-membered heteroaryl; W is a zinc-binding group; each R2 is independently hydrogen or C1-C6 alkyl; and R3 is an aryl or heteroaryl. The compounds are useful as histone deacetylase (HDAC) inhibitors.Type: GrantFiled: October 29, 2015Date of Patent: January 14, 2020Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Somhairle MacCormick, William John Nodes, Cyrille Davy Tomassi, Franck Alexandre Silva
-
Patent number: 10513530Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1-C10 alkylene, C2-C10 alkenylene or C2-C10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C10 alkyl, halogen, fluoro C1-C10 alkyl, O— C1-C10 alkyl, NH—C1-C10 alkyl, S—C1-C10 alkyl, O-fluoro C1-C10 alkyl, NH-acyl, NH—C(O)—NH—C1-C10 alkyl, C(O)—NH—C1-C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110?, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.Type: GrantFiled: April 24, 2018Date of Patent: December 24, 2019Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Franck Alexandre Silva
-
Patent number: 10501478Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is (LQ)mY; and each R3 is independently H, C1-C10alkyl, aryl or heteroaryl, are surprisingly found to be inhibitors of PI3K-p110?, and therefore have utility in therapy.Type: GrantFiled: March 1, 2018Date of Patent: December 10, 2019Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Thomas James Hill, Franck Alexandre Silva
-
Patent number: 10442815Abstract: The invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof and/or stereoisomers thereof. The compounds of the invention are useful in therapy.Type: GrantFiled: August 19, 2016Date of Patent: October 15, 2019Assignee: Karus Therapeutics LimitedInventors: Stephen J. Shuttleworth, Franck A. Silva, Alexander R. L. Cecil, Rikki P. Alexander, Alice E. Gatland, Daniel J. Finnemore
-
Patent number: 10407435Abstract: The present invention is a compound having the following formula: (Formula (I)) or a pharmaceutically acceptable salt thereof, wherein e.g. X is C or N; n is 1 to 10; each L is independently a 5- to 12-membered heteroaryl containing at least two nitrogen atoms; and W is a zinc-binding group. The compounds are useful as histone deacetylase (HDAC) inhibitors.Type: GrantFiled: October 29, 2015Date of Patent: September 10, 2019Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Somhairle MacCormick, William John Nodes, Cyrille Davy Tomassi
-
Patent number: 10377764Abstract: The invention relates to a compound of formula I: (I) or a pharmaceutically acceptable salt thereof, wherein each R3 is independently selected from H, halo, fluorinated C1-C10 alkyl, —I—C1-C10 alkyl, —NH—C1-C10 alkyl, —S—C1-C10 alkyl, —O-fluorinated C1-C10 alkyl, —NH-acyl, —NH—C(O)—NH-alkyl, —C—(O)—NH-alkyl, with the proviso that at least one of R3 is not H.Type: GrantFiled: August 19, 2016Date of Patent: August 13, 2019Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Franck Alexandre Silva, Alexander Richard Liam Cecil, Alice Elizabeth Gatland, Daniel John Finnemore
-
Patent number: 10150763Abstract: A compound of the formula:(I) or a pharmaceutically acceptable salt thereof, wherein: L is a 5-membered nitrogen-containing heteroaryl which is optionally fused to a benzene; Y is a 5, 6 or 7-membered nitrogen-containing heteroaryl, which is optionally fused to a benzene; and W is a zinc-binding group. The compounds are HDAC inhibitors and therefore have potential utility in therapy.Type: GrantFiled: May 8, 2017Date of Patent: December 11, 2018Assignee: Karus Therapeutics LimitedInventors: Stephen J. Shuttleworth, Cyrille D. Tomassi, Alexander R. Cecil, Somhairle MacCormick, William J. Nodes, Franck A. Silva
-
Patent number: 10035785Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R3, R and R6 are each independently (LQ)mY; R4 is H, halogen, optionally substituted aryl or optionally substituted alkyl; and; each X is independently CR7 or N. The compounds are PI3K inhibitors and therefore have potential utility in therapy.Type: GrantFiled: April 25, 2017Date of Patent: July 31, 2018Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Franck Alexandre Silva
-
Patent number: 9981987Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1-C10 alkylene, C2-C10 alkenylene or C2-C10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C10 alkyl, halogen, fluoro C1-C10 alkyl, O—C1-C10 alkyl, NH—C1-C10 alkyl, S—C1-C10 alkyl, O-fluoro C1-C10 alkyl, NH-acyl, NH—C(O)—NH—C1-C10 alkyl, C(O)—NH—C1-C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110?, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.Type: GrantFiled: February 12, 2015Date of Patent: May 29, 2018Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Franck Alexandre Silva
-
Patent number: 9938290Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is (LQ)mY; and each R3 is independently H, C1-C10 alkyl, aryl or heteroaryl, are surprisingly found to be inhibitors of PI3K-p110?, and therefore have utility in therapy.Type: GrantFiled: January 19, 2017Date of Patent: April 10, 2018Assignee: Karus Therapeutics LimitedInventors: Stephen J. Shuttleworth, Alexander R. Liam Cecil, Thomas J. Hill, Franck A. Silva
-
Patent number: 9862685Abstract: The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors.Type: GrantFiled: May 12, 2014Date of Patent: January 9, 2018Assignee: Karus Therapeutics LimitedInventors: Stephen J. Shuttleworth, Cyrille D. Tomassi, Alexander R. L. Cecil, Somhairle MacCormick, William J. Nodes, Franck A. Silva
-
Patent number: 9676765Abstract: A compound of the formula: (I) or a pharmaceutically acceptable salt thereof, wherein: L is a 5-membered nitrogen-containing heteroaryl which is optionally fused to a benzene; Y is a 5, 6 or 7-membered nitrogen-containing heteroaryl, which is optionally fused to a benzene; and W is a zinc-binding group. The compounds are HDAC inhibitors and therefore have potential utility in therapy.Type: GrantFiled: November 6, 2013Date of Patent: June 13, 2017Assignee: Karus Therapeutics LimitedInventors: Stephen J. Shuttleworth, Cyrille D. Tomassi, Alexander R. Cecil, Somhairle Maccormick, William J. Nodes, Franck A. Silva
-
Patent number: 9663487Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R3, R and R6 are each independently (LQ)mY; R4 is H, halogen, optionally substituted aryl or optionally substituted alkyl; and; each X is independently CR7 or N. The compounds are PI3K inhibitors and therefore have potential utility in therapy.Type: GrantFiled: March 8, 2013Date of Patent: May 30, 2017Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Franck Alexandre Silva
-
Patent number: 9580442Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is (LQ)mY; and each R3 is independently H, C1-C10 alkyl, aryl or heteroaryl, are surprisingly found to be inhibitors of PI3K-p110?, and therefore have utility in therapy.Type: GrantFiled: October 22, 2015Date of Patent: February 28, 2017Assignee: Karus Therapeutics LimitedInventors: Stephen J. Shuttleworth, Alexander R. Liam Cecil, Thomas J. Hill, Franck A. Silva
-
Patent number: 9340503Abstract: Compounds of the invention are of the formula wherein: is a double bond and X is C; or is a single bond and X is N, CH or CQR1; and wherein: n is 1 to 10; R is H or QR1; each R? is independently selected from H and QR1; each Q is independently selected from a bond, CO, NH, S, SO, SO2 or O; each R1 is independently selected from C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, substituted or unsubstituted aryl or heteroaryl, acyl, C1-C10 cycloalkyl, halogen, C1-C10 alkylaryl or C1-C10 heterocycloalkyl; L is a nitrogen-containing heteroaryl; and W is a zinc-chelating residue; or a pharmaceutically acceptable salt thereof. The compounds are useful in therapy.Type: GrantFiled: April 30, 2014Date of Patent: May 17, 2016Assignee: Karus Therapeutics, LimitedInventors: Stephen Joseph Shuttleworth, Cyrille Davy Tomassi
-
Patent number: 9266879Abstract: Compounds of formulae (I) and (II): or a pharmaceutically acceptable salt thereof, wherein: R1 is a nitrogen-containing 5 to 7-membered heteroaryl or heterocycle; R2 and R3 are each independently (LQ)mY, are described. The compounds are PI3K inhibitors and are useful for the treatment of cancer and immune-inflammatory diseases.Type: GrantFiled: April 26, 2011Date of Patent: February 23, 2016Assignee: Karus Therapeutic LimitedInventors: Stephen Joseph Shuttleworth, Franck Alexandre Silva
-
Patent number: 9200007Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N-(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is (LQ)mY; and each R3 is independently H, C1-C10 alkyl, aryl or heteroaryl, are surprisingly found to be inhibitors of PI3K-p110?, and therefore have utility in therapy.Type: GrantFiled: August 19, 2010Date of Patent: December 1, 2015Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Thomas James Hill, Franck Alexandre Silva